Guangdong Taienkang Pharmaceutical Co., Ltd.

SZSE:301263 Stock Report

Market Cap: CN¥12.9b

Guangdong Taienkang Pharmaceutical Management

Management criteria checks 4/4

Guangdong Taienkang Pharmaceutical's CEO is Hanjie Zheng, appointed in Nov 2011, has a tenure of 14.17 years. directly owns 20.87% of the company’s shares, worth CN¥2.70B. The average tenure of the management team and the board of directors is 4.8 years and 7 years respectively.

Key information

Hanjie Zheng

Chief executive officer

CN¥437.1k

Total compensation

CEO salary percentagen/a
CEO tenure14.2yrs
CEO ownership20.9%
Management average tenure4.8yrs
Board average tenure7yrs

Recent management updates

Recent updates

Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Somewhat Strained Balance Sheet

Mar 10
Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Somewhat Strained Balance Sheet

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Popularity With Investors Is Clear

Feb 11
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) Popularity With Investors Is Clear

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Meaningful Debt Burden

Nov 20
Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Meaningful Debt Burden

Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Sep 03
Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Aug 23
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Jul 22
Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

May 22
Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Feb 26
Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

CEO

Hanjie Zheng (62 yo)

14.2yrs
Tenure
CN¥437,100
Compensation

Mr. Hanjie Zheng is GM & Chairman of Guangdong Taienkang Pharmaceutical Co., Ltd. from November 17, 2011.

Leadership Team

NamePositionTenureCompensationOwnership
Hanjie Zheng
GM & Chairman14.2yrsCN¥437.10k20.87%
CN¥ 2.7b
Guixi Zhou
Accounting Supervisor & Financial Director3.1yrsCN¥303.60kno data
Chun Chen
Director & Deputy GM14.2yrsCN¥275.00kno data
Ting Li
Director6yrsCN¥320.10k0.13%
CN¥ 17.1m
Tao Sun
Deputy General Manager3.6yrsCN¥360.40kno data
Zhen Zhang
Deputy General Manager3.6yrsCN¥783.20k1.42%
CN¥ 184.1m
4.8yrs
Average Tenure
49yo
Average Age

Experienced Management: 301263's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hanjie Zheng
GM & Chairman14.2yrsCN¥437.10k20.87%
CN¥ 2.7b
Chun Chen
Director & Deputy GM14.2yrsCN¥275.00kno data
Ting Li
Director6yrsCN¥320.10k0.13%
CN¥ 17.1m
Weiwen Sun
Vice Chairman13.8yrsno data15.64%
CN¥ 2.0b
Chaohui Peng
Independent Director1.9yrsCN¥64.20kno data
Zili Lin
Chairman of the Supervisory Board14.2yrsno datano data
Jian-Xin Wang
Supervisor7.9yrsno datano data
Ying Liang
Supervisor3.6yrsno datano data
Yiyong Shen
Independent Director1.9yrsCN¥64.20kno data
Xiaowei Chen
Independent Director1.9yrsCN¥64.20kno data
7.0yrs
Average Tenure
56.5yo
Average Age

Experienced Board: 301263's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/16 15:24
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guangdong Taienkang Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xinming ZhouTopsperity Securities